NCT02710240View on ClinicalTrials.gov

Indocyanine Green for Central Nervous System Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

February 4, 2020

Study Completion Date

April 2, 2020

Conditions
Suspected Central Nervous System Tumors
Interventions
DRUG

Indocyanine Green (ICG)

RADIATION

Intraoperative near-infrared (NIR)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02710240 - Indocyanine Green for Central Nervous System Tumors | Biotech Hunter | Biotech Hunter